Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 28.67M | 25.16M | 12.49M | 9.39M | 7.63M | 611.83K |
Gross Profit | 10.49M | 8.46M | 3.68M | 2.22M | 4.63M | 371.40K |
EBITDA | -1.51M | -2.01M | -4.50M | -3.01M | 653.98K | -245.00K |
Net Income | -3.49M | -3.97M | -5.31M | -3.09M | -278.00K | -237.00K |
Balance Sheet | ||||||
Total Assets | 16.17M | 14.85M | 12.73M | 7.28M | 6.68M | 1.13M |
Cash, Cash Equivalents and Short-Term Investments | 1.33M | 639.09K | 971.96K | 1.35M | 725.02K | 1.12M |
Total Debt | 1.03M | 894.64K | 180.90K | 356.08K | 475.04K | 484.31K |
Total Liabilities | 16.01M | 14.32M | 10.04M | 2.39M | 1.93M | 18.27K |
Stockholders Equity | 166.40K | 534.88K | 2.69M | 4.89M | 4.75M | 1.11M |
Cash Flow | ||||||
Free Cash Flow | -1.05M | -534.84K | -568.67K | -312.71K | -707.55K | -637.10K |
Operating Cash Flow | -1.03M | -96.89K | -271.30K | -50.09K | -198.56K | -235.95K |
Investing Cash Flow | -25.19K | -437.94K | -297.38K | -262.62K | 363.25K | -401.15K |
Financing Cash Flow | -528.53K | -48.03K | 185.82K | 942.51K | 537.89K | 245.24K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | C$6.25M | -40.82 | ― | ― | 4.04% | 80.24% | |
51 Neutral | C$7.79M | ― | -271.33% | ― | 27.80% | 31.16% | |
49 Neutral | C$420.72K | -0.31 | ― | ― | -100.00% | 43.66% | |
39 Underperform | C$4.58M | -0.18 | ― | ― | -34.09% | 71.95% | |
38 Underperform | C$10.63M | -1.83 | ― | ― | -100.00% | -8.70% | |
31 Underperform | C$2.42M | -0.64 | ― | ― | 563.34% | -68.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Ayurcann Holdings Corp. reported record-breaking financial results for Q3 2025, with a gross revenue of $14,179,974, marking a 22% year-over-year increase. The company has achieved significant market share, being a top 3 vape producer in Ontario and holding a 5% national market share. With a focus on operational efficiency and a growing national footprint, Ayurcann is well-positioned for sustainable growth, despite industry challenges. The company is actively expanding its product categories and geographic reach to drive future revenue growth.